Naotaka Uchida1, Takako Suda, Kiyosuke Ishiguro. 1. Clinic of Surgery, Tottori Prefectural Kosei Hospital, Kurayoshi 682-0804, Japan ; †Clinical Department of Mammoendocrinology, Tottori University Hospital, Yonago 683-8504, Japan.
Abstract
BACKGROUND: The addition of chemotherapy to endocrine therapy for luminal A breast cancer generally provides little benefit. However, the least benefit of chemotherapy in all patients with luminal A breast cancer is controversial. METHODS: This was a retrospective study of 140 patients with luminal A breast cancer who underwent surgery at Tottori University Hospital between 2001 and 2010. Luminal A breast cancer was defined as positive for estrogen receptors and/or progesterone receptors and negative for human epidermal growth factor 2. Postoperative endocrine therapy was given to all patients. The prognostic values of age, tumor size, presence of lymphovascular invasion and lymph node status were evaluated. In addition, the prognostic value of chemotherapy for patients with identified risk factors affecting relapse-free survival and overall survival was evaluated. RESULTS: Tumor size greater than 2 cm and positive lymph node status were factors significantly affecting relapse-free survival. There were no factors significantly affecting overall survival. There was no significant difference in the relapse-free survival of patients with tumor size greater than 2 cm and/or positive lymph node status who either received chemotherapy or not. However, the relapse event was earlier in patients with tumor size greater than 2 cm and positive lymph node status who did not receive chemotherapy than in those who received chemotherapy. CONCLUSION: Chemotherapy could provide little benefit to patients with luminal A breast cancer. However, chemotherapy may bring them longer relapse-free periods.
BACKGROUND: The addition of chemotherapy to endocrine therapy for luminal A breast cancer generally provides little benefit. However, the least benefit of chemotherapy in all patients with luminal A breast cancer is controversial. METHODS: This was a retrospective study of 140 patients with luminal A breast cancer who underwent surgery at Tottori University Hospital between 2001 and 2010. Luminal A breast cancer was defined as positive for estrogen receptors and/or progesterone receptors and negative for human epidermal growth factor 2. Postoperative endocrine therapy was given to all patients. The prognostic values of age, tumor size, presence of lymphovascular invasion and lymph node status were evaluated. In addition, the prognostic value of chemotherapy for patients with identified risk factors affecting relapse-free survival and overall survival was evaluated. RESULTS:Tumor size greater than 2 cm and positive lymph node status were factors significantly affecting relapse-free survival. There were no factors significantly affecting overall survival. There was no significant difference in the relapse-free survival of patients with tumor size greater than 2 cm and/or positive lymph node status who either received chemotherapy or not. However, the relapse event was earlier in patients with tumor size greater than 2 cm and positive lymph node status who did not receive chemotherapy than in those who received chemotherapy. CONCLUSION: Chemotherapy could provide little benefit to patients with luminal A breast cancer. However, chemotherapy may bring them longer relapse-free periods.
Authors: Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-23 Impact factor: 44.544
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Eleftherios P Mamounas; John Bryant; Barry Lembersky; Louis Fehrenbacher; Scot M Sedlacek; Bernard Fisher; D Lawrence Wickerham; Greg Yothers; Atilla Soran; Norman Wolmark Journal: J Clin Oncol Date: 2005-05-16 Impact factor: 44.544
Authors: Christos Sotiriou; Soek-Ying Neo; Lisa M McShane; Edward L Korn; Philip M Long; Amir Jazaeri; Philippe Martiat; Steve B Fox; Adrian L Harris; Edison T Liu Journal: Proc Natl Acad Sci U S A Date: 2003-08-13 Impact factor: 11.205
Authors: Judith Hugh; John Hanson; Maggie Chon U Cheang; Torsten O Nielsen; Charles M Perou; Charles Dumontet; John Reed; Maryla Krajewska; Isabelle Treilleux; Matthieu Rupin; Emmanuelle Magherini; John Mackey; Miguel Martin; Charles Vogel Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Maura Bríd Cotter; Alex Dakin; Aoife Maguire; Janice M Walshe; M John Kennedy; Barbara Dunne; Ciarán Ó Riain; Cecily M Quinn Journal: Virchows Arch Date: 2017-07-14 Impact factor: 4.064
Authors: Thomas Kieber-Emmons; Issam Makhoul; Angela Pennisi; Eric R Siegel; Peter D Emanuel; Bejotaloh Monzavi-Karbassi; Zenon Steplewski; J Thaddeus Beck; Laura F Hutchins Journal: Rev Recent Clin Trials Date: 2017
Authors: Joachim Diessner; Manfred Wischnewsky; Maria Blettner; Sebastian Häusler; Wolfgang Janni; Rolf Kreienberg; Roland Stein; Tanja Stüber; Lukas Schwentner; Catharina Bartmann; Achim Wöckel Journal: PLoS One Date: 2016-12-19 Impact factor: 3.240
Authors: Johannes Uhlig; Uwe Fischer; Eva von Fintel; Vera Stahnke; Christina Perske; Joachim Lotz; Susanne Wienbeck Journal: Transl Oncol Date: 2017-09-22 Impact factor: 4.243